Search

Your search keyword '"Rimawi M"' showing total 8 results
Start Over Author "Rimawi M" Journal annals of oncology
8 results on '"Rimawi M"'

1. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker

Author

Mayer, E.L., Abramson, V., Jankowitz, R., Falkson, C., Marcom, P.K., Traina, T., Carey, L., Rimawi, M., Specht, J., Miller, K., Stearns, V., Tung, N., Perou, C., Richardson, A.L., Componeschi, K., Trippa, L., Tan-Wasielewski, Z., Timms, K., Krop, I., Wolff, A.C., and Winer, E.P.

Published
2020
Full Text
View/download PDF

2. 191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026)

Author

Hennessy, M.A., primary, Leal, J., additional, Huang, C-Y., additional, Solnes, L., additional, Denbow, R., additional, Abramson, V., additional, Carey, L., additional, Liu, M.C., additional, Rimawi, M., additional, Specht, J., additional, Storniolo, A.M.V., additional, Valero, V., additional, Vaklavas, C., additional, Winer, E., additional, Krop, I., additional, Wolff, A.C., additional, Cimino-Mathews, A., additional, Wahl, R., additional, Stearns, V., additional, and Connolly, R.M., additional

Published
2022
Full Text
View/download PDF

3. 328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09

Author

Tolaney, S.M., primary, Barroso-Sousa, R., additional, Jiang, Z., additional, Park, Y.H., additional, Rimawi, M., additional, Saura Manich, C., additional, Schneeweiss, A., additional, Toi, M., additional, Yu, T., additional, Shetty, J., additional, Herbolsheimer, P., additional, and Loibl, S., additional

Published
2021
Full Text
View/download PDF

6. ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials

Author

Chic, N., primary, Pascual, T., additional, Brasó-Maristany, F., additional, Villagrasa Gonzalez, P., additional, Pare Brunet, L., additional, Schettini, F., additional, Conte, B., additional, Adamo, B., additional, Vidal, M., additional, Muñoz, M., additional, Martínez, O., additional, Gonzalez-Farre, B., additional, Cortés, J., additional, Llombart-Cussac, A., additional, Rodrik-Outmezguine, V., additional, Izquierdo Delso, M.A., additional, Schiff, R., additional, Osborne, C.K., additional, Rimawi, M., additional, and Prat, A., additional

Published
2019
Full Text
View/download PDF

7. 119P - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials

Author

Chic, N., Pascual, T., Brasó-Maristany, F., Villagrasa Gonzalez, P., Pare Brunet, L., Schettini, F., Conte, B., Adamo, B., Vidal, M., Muñoz, M., Martínez, O., Gonzalez-Farre, B., Cortés, J., Llombart-Cussac, A., Rodrik-Outmezguine, V., Izquierdo Delso, M.A., Schiff, R., Osborne, C.K., Rimawi, M., and Prat, A.

Published
2019
Full Text
View/download PDF

8. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

Author

Rachel Schiff, Mothaffar F. Rimawi, Matthew P. Goetz, Jorge S. Reis-Filho, Ting Wang, Britta Weigelt, Carolina Gutierrez, CK Osborne, Aleix Prat, Suzanne A. W. Fuqua, Antonio C. Wolff, R. Mao, Jamunarani Veeraraghavan, Andres Forero, Anna C. Pavlick, Paolo Nuciforo, Ingrid A. Mayer, C. De Angelis, SG Hilsenbeck, Jenny C. Chang, Ian E. Krop, Rita Nanda, Sabrina Herrera, Alejandro Contreras, De Angelis, C., Veeraraghavan, J., Mao, R., Wang, T., Herrera, S., Pavlick, A. C., Contreras, A., Nuciforo, P., Mayer, I. A., Forero, A., Nanda, R., Goetz, M. P., Chang, J. C., Wolff, A. C., Krop, I. E., Fuqua, S. A. W., Prat, A., Hilsenbeck, S. G., Weigelt, B., Reis-Filho, J. S., Gutierrez, C., Osborne, C. K., Rimawi, M. F., and Schiff, R.

Subjects
0301 basic medicine, Oncology, Receptor, ErbB-2, medicine.medical_treatment, Estrogen receptor, PIK3CA mutation, Phosphatidylinositol 3-Kinases, 0302 clinical medicine, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, PTEN protein, skin and connective tissue diseases, In Situ Hybridization, Fluorescence, Neoadjuvant therapy, biology, Remission Induction, Hematology, Prognosis, Chemotherapy regimen, Neoadjuvant Therapy, 030220 oncology & carcinogenesis, Female, medicine.drug, medicine.medical_specialty, Class I Phosphatidylinositol 3-Kinases, precision medicine, Breast Neoplasms, Lapatinib, 03 medical and health sciences, breast cancer, Breast cancer, Internal medicine, Biomarkers, Tumor, medicine, Humans, PTEN, neoplasms, Chemotherapy, business.industry, ErbB2 receptor tyrosine kinase, Gene Amplification, Original Articles, medicine.disease, 030104 developmental biology, fluorescent in situ hybridization, biology.protein, business, Follow-Up Studies
Abstract

BACKGROUND: HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2 therapy. We hypothesize that HER2 amplification levels and PI3K pathway activation are key determinants of response to HER2-targeted treatments without chemotherapy. PATIENTS AND METHODS: Baseline HER2+ tumors from patients treated with neoadjuvant lapatinib plus trastuzumab [with endocrine therapy for estrogen receptor (ER)+ tumors] in TBCRC006 (NCT00548184) were evaluated in a central laboratory for HER2 amplification by fluorescence in situ hybridization (FISH) (n = 56). HER2 copy number (CN) and FISH ratios, and PI3K pathway status, defined by PIK3CA mutations or PTEN levels by immunohistochemistry were available for 41 tumors. Results were correlated with pathologic complete response (pCR; no residual invasive tumor in breast). RESULTS: Thirteen of the 56 patients (23%) achieved pCR. None of the 11 patients with HER2 ratio

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results